Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Immunology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clim.2007.12.001PMID 18262845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The use of dendritic cells in cancer immunotherapy.

  2008cited by this paper
• Peptide-based immunotherapeutic approaches to glioma: a review

  2007cited by this paper
• Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials

  2006cited by this paper
• Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

  2006cited by this paper
• Overview of Tumor Cell–Based Vaccines

  2006cited by this paper
• Promises and Limitations of Murine Models in the Development of Anticancer T-Cell Vaccines

  2006cited by this paper
• Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.

  2005cited by this paper
• Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.

  2004cited by this paper
• Comparative Analysis of Antigen Loading Strategies of Dendritic Cells for Tumor Immunotherapy

  2004cited by this paper
• Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo

  2004cited by this paper
• Tumor-Dendritic Cell Fusion as a Basis for Cancer Immunotherapy

  2004cited by this paper
• Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1

  2004cited by this paper
• Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

  2004cited by this paper
• Tumor-dendritic cell fusion as a basis for cancer immunotherapy

  2004cited by this paper
• The use of dendritic cells in cancer immunotherapy.

  2003cited by this paper
• Adoptive-cell-transfer therapy for the treatment of patients with cancer

  2003cited by this paper
• Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine.

  2003cited by this paper
• Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells.

  2003cited by this paper
• Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1

  2003cited by this paper
• Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion.

  2002cited by this paper
• Therapeutic immune response induced by electrofusion of dendritic and tumor cells.

  2002cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor1

  2001cited by this paper
• Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression

  2001cited by this paper
• Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1

  2000cited by this paper
• CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

  2000cited by this paper
• T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-γ Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics1

  2000cited by this paper
• Follow-up after treatment of primary breast cancer.

  1999cited by this paper
• T-cell adoptive immunotherapy of metastatic renal cell carcinoma.

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression.

  1999cited by this paper
• Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.

  1996cited by this paper
• Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

  1995cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.

  1993cited by this paper
• Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.

  1992cited by this paper
• Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

  1991cited by this paper
• Leukocyte integrin P150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium.

  1991cited by this paper
• Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

  1991cited by this paper
• Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

  1990cited by this paper
• Follow‐up after treatment of primary breast cancer

  1989cited by this paper
• Screening for recurrent breast cancer--its effectiveness and prognostic value.

  1987cited by this paper
• Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.

  1987cited by this paper
• Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.

  1986cited by this paper
• In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.

  1986cited by this paper
• Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

  1985cited by this paper
• Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability.

  1983cited by this paper
• Heterogeneity of tumor cells from a single mouse mammary tumor.

  1978cited by this paper
• Accurate identification of experimental pulmonary metastases.

  1966cited by this paper

• Understanding the squamous cell carcinoma immune microenvironment

  2023cites this paper
• Vaccine-Enhanced Adoptive T-Cell Therapy to Treat Canine Cancers

  2021cites this paper
• Cell Therapy: Types, Regulation, and Clinical Benefits

  2021cites this paper
• Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma

  2020cites this paper
• Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

  2020cites this paper
• Single vs. combination immunotherapeutic strategies for glioma

  2017cites this paper
• Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists

  2016cites this paper
• Dendritic Cell-Based Vaccination in Cancer: Therapeutic Implications Emerging from Murine Models

  2015cites this paper
• Trends in Adoptive Tumor Infiltrating Lymphocytes (TILs) Therapy

  2015cites this paper
• Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

  2015cites this paper
• Various ways to improve whole cancer cell vaccines

  2014cites this paper
• A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

  2014cites this paper
• Increased Tc22 and Treg/CD8 Ratio Contribute to Aggressive Growth of Transplant Associated Squamous Cell Carcinoma

  2013cites this paper
• The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor

  2013cites this paper
• Macrophages mediate colon carcinoma cell adhesion in the rat liver after exposure to lipopolysaccharide

  2012cites this paper
• Dendritic cells-based cancer vaccine

  2012cites this paper
• Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

  2011cites this paper
• The 'Gator' Mouse Suit for early bioluminescent metastatic breast cancer detection and nanomaterial signal enhancement during live animal imaging.

  2011cites this paper
• Immune response to cancer and its regulation in regional lymph nodes

  2011cites this paper
• Cell Fusion and Dendritic Cell-Based Vaccines

  2011cites this paper
• Semiallogenic fusions of MSI+ tumor cells and activated B cells induce MSI-specific T cell responses

  2011cites this paper
• ' s response to reviews Title : Semiallogenic fusions of MSI + tumor cells and activated B cells induce MSI-specific T cell responses

  2011cites this paper
• Significant anti‐tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+ T cell/regulatory T cells in tumour

  2010cites this paper
• J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.

  2010cites this paper
• Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

  2010cites this paper
• J-LEAPS VACCINES ARE SUFFICIENT TO ACTIVATE AND DIRECT AN IMMUNE RESPONSE THROUGH DENDRITIC CELLS

  2010cites this paper
• Cancer Vaccine by Fusions of Dendritic and Cancer Cells

  2010cites this paper
• Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells

  2010cites this paper
• Radiotherapy Combined With Intratumoral Dendritic Cell Vaccination Enhances the Therapeutic Efficacy of Adoptive T-cell Transfer

  2009influential citation
• Characterization of Dendritic Cells in the Bovine Mammary Gland

  2009cites this paper
• Cancer immunotherapy by fusions of dendritic cells and tumor cells.

  2009cites this paper
• Cell fusion: from hybridoma to dendritic cell-based vaccine

  2008cites this paper